Flutiform® Compared With Seretide® in the Treatment of COPD

NCT02195375 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

923

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Flutiform 500/20 µg BID
DRUG: Flutiform 250/10 µg BID
DRUG: Seretide Accuhaler 50/500 µg BID

Sponsor

Mundipharma Research Limited